Schrödinger strikes AI drug discovery deal with Bristol Myers Squibb

Schrödinger, Inc. (Nasdaq: SDGR) announced a strategic software agreement with Bristol Myers Squibb to deploy Bunsen, Schrödinger's AI co-scientist tool, within BMS's research organization.

Under the agreement, Schrödinger will collaborate with BMS scientists to develop new functionality within Bunsen alongside its computational technologies and RetroSynth, its AI-driven synthesis planning platform. The deal expands on an existing partnership between the two companies.

Bunsen is designed to plan and run molecular discovery workflows using Schrödinger's physics-based computational methods. The tool is intended to help research teams evaluate hypotheses, explore chemical space, and support decision-making ahead of experimental testing.

Robert Abel, Chief Scientific Officer, Platform, at Schrödinger, said the expanded agreement would "empower a broader group of scientists to embrace a predict-first computational approach."

Stephen Johnson, Vice President of Computational Sciences at Bristol Myers Squibb, said Bunsen "allows our scientists to think differently about how physics-based tools can be used to navigate molecular design space and accelerate the discovery of innovative medicines for patients."

The press release did not disclose financial terms of the agreement.

You May Also Be Interested In

• Teva plans senior notes offering to refinance existing debt
• UiPath names new CFO and adds board member amid leadership reshuffle
• Roivant to present Phase 2 mosliciguat data at ERS Congress Sept. 8